drugset / Trial / NCT01644331

Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure

NCT01644331

Phase 3 Completed 257 enrolled Duke University
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to compare the effects of oral Tolvaptan vs. placebo as an adjunct to fixed dose IV furosemide on dyspnea relief in patients with acute decompensated heart failure The primary hypothesis is that the addition of oral Tolvaptan to fixed dose furosemide will be more effective at relieving dyspnea than fixed dose furosemide alone

Timeline

Start
2012-10
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolvaptan Small molecule 30 mg Oral